Monsanto drops takeover bid for Syngenta
Aug. 27, 2015
Related News
- Monsanto struggling to engage Syngenta in deal talks
- Syngenta AG jumps almost 8%, ChemChina considering $44 bn cash bid for it
- Monsanto mulls another takeover for Syngenta
- Monsanto to focus on big data business after failed Syngenta bid
- What's next for Monsanto, Syngenta?
- Monsanto increased Syngenta takeover offer to about $47 billion
- Syngenta rejects Monsanto’s second takeover
- Syngenta rejects $45 billion Monsanto takeover offer
Monsanto has dropped its bid for Syngenta after the Swiss agrochemical producer rejected its latest offer of nearly $47 billion.
A combination with Basel-based Syngenta would have made Monsanto the world's largest producer of agrochemicals, in addition to its market-leading seed business. But the Swiss pesticide maker rejected a series of unsolicited offers from the American company.
Monsanto confirmed Wednesday that it had raised its offer last week to 470 francs per share, or nearly $47 billion, from a previous offer of about $45 billion.
Additionally, the company confirmed it had raised its proposed breakup fee to $3 billion from $2 billion. That's the amount Monsanto would have paid Syngenta if it had been unable to get regulatory approval to complete the deal.
But Monsanto says the enhanced offer "did not meet Syngenta's financial expectations." The St. Louis-based company said in a statement it would "continue to focus on its growth opportunities built on its existing core business."
Syngenta said in Wednesday that its board of directors unanimously rejected Monsanto's latest offer, which "significantly undervalued the company and was fraught with execution risk."
The company said Monsanto did not adequately address several issues, including potential cost savings and the risks of reincorporating the combined company in the United Kingdom.
Merging with Syngenta would have helped Monsanto diversify its chemical offerings beyond Roundup, the ubiquitous weed killer that long served as the cornerstone of Monsanto's business. Sales of that chemical have been hurt in recent months by concerns about its safety when used in large-scale industrial farming.
In March the International Agency for Research on Cancer labeled the Roundup's key ingredient, glyphosate, a "probable carcinogen." The company has demanded a retraction from the group, a French research arm of the World Health Organization.
A combination with Basel-based Syngenta would have made Monsanto the world's largest producer of agrochemicals, in addition to its market-leading seed business. But the Swiss pesticide maker rejected a series of unsolicited offers from the American company.
Monsanto confirmed Wednesday that it had raised its offer last week to 470 francs per share, or nearly $47 billion, from a previous offer of about $45 billion.
Additionally, the company confirmed it had raised its proposed breakup fee to $3 billion from $2 billion. That's the amount Monsanto would have paid Syngenta if it had been unable to get regulatory approval to complete the deal.
But Monsanto says the enhanced offer "did not meet Syngenta's financial expectations." The St. Louis-based company said in a statement it would "continue to focus on its growth opportunities built on its existing core business."
Syngenta said in Wednesday that its board of directors unanimously rejected Monsanto's latest offer, which "significantly undervalued the company and was fraught with execution risk."
The company said Monsanto did not adequately address several issues, including potential cost savings and the risks of reincorporating the combined company in the United Kingdom.
Merging with Syngenta would have helped Monsanto diversify its chemical offerings beyond Roundup, the ubiquitous weed killer that long served as the cornerstone of Monsanto's business. Sales of that chemical have been hurt in recent months by concerns about its safety when used in large-scale industrial farming.
In March the International Agency for Research on Cancer labeled the Roundup's key ingredient, glyphosate, a "probable carcinogen." The company has demanded a retraction from the group, a French research arm of the World Health Organization.
Source: finance.yahoo
More from AgroNews
Subscribe
| Subscribe Email: | * | |
| Name: | ||
| Mobile Number: | ||
Comment
Picture 0/1200
Subscribe to daily email alerts of AgroNews.